SIRION BIOTECH
SIRION Biotech, founded in 2007 in Martinsried, Germany, developed AAV, lentivirus, and adenovirus viral vector technologies and custom manufacturing services for pharma, biotech, academic, and CRO customers in gene therapy and vaccine research. Acquired by Revvity in 2021.
- Company typePrivate
- Founded2007
- HeadquartersMartinsried, Germany
- Headcount11–50
- GTM typeB2B
- OfferingServices
What SIRION BIOTECH does
SIRION Biotech is a German biotechnology company founded in 2007 and headquartered in Martinsried, specializing in viral vector technologies for gene therapy, cell therapy, and vaccine research. Its core technology portfolio spans three platforms — adeno-associated virus (AAV), lentivirus (LV), and adenovirus (AV) — supported by proprietary assets including the LentiBOOST transduction enhancer, the Ad19a/64 adenoviral vector (Subtype D) designed to overcome pre-existing immunity, and AAV capsid evolution and nanobody targeting capabilities. The company offers a mix of catalog products (notably AAV reference standards for gene therapy assay reproducibility) and custom viral vector engineering and manufacturing services for pharma, biotech, academic, and contract research customers at the discovery and preclinical stages.
The company operated an enterprise sales-led go-to-market with custom services priced on a quote basis, alongside e-commerce availability of standard reference materials (e.g., rAAV8 reference standard at USD 400 per unit). It also coordinated access to a global CDMO network developed over approximately five years, recommending contract manufacturers matched to customer location and project requirements. The company was acquired by Revvity (NYSE: RVTY) in 2021, with its expertise and offerings integrated into Revvity's gene delivery portfolio and now distributed through Revvity's global sales infrastructure and regional e-commerce sites spanning the US, UK, Germany, France, Japan, China, and India. Prior to the acquisition, the company had 11-50 employees and had raised venture funding from Bayern Kapital, Creathor Ventures, HTGF, and KfW in 2011 and 2013.
SIRION BIOTECH firmographics
Firmographics- Name
- SIRION BIOTECH
- Website
- https://sirion-biotech.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- SIRION Biotech, founded in 2007 in Martinsried, Germany, developed AAV, lentivirus, and adenovirus viral vector technologies and custom manufacturing services for pharma, biotech, academic, and CRO customers in gene therapy and vaccine research. Acquired by Revvity in 2021.
- Ownership category
- akta.pro rank
SIRION BIOTECH industry classification
Industry- Product category
- Gene Therapy Viral Vector CDMO
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)
- akta.pro secondary industries
- Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA) (HLAAACAK)
Keywords
Where SIRION BIOTECH is headquartered
LocationHeadquarters
- HQ city
- Martinsried
- HQ country
- Germany
- HQ region
- Europe
Markets served
SIRION BIOTECH business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Viral Vector Products and Services: Sale of viral vector products including AAV reference standards and viral vector development and manufacturing services for pharma and biotech organizations. Services cover adeno-associated viruses (AAVs), lentiviruses (LV) and Adenoviruses (AVs) for early discovery and preclinical research stages.
- Custom Manufacturing Services: Individualized and customized solutions tailored to fit viral vector projects at all stages of discovery and development, ensuring fast and cost-effective product manufacture.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | AAV Reference Standard Material |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
SIRION BIOTECH product offering
Product offeringCore offering
SIRION Biotech develops and manufactures viral vector technologies (lentiviral, AAV, and adenoviral) for gene therapy applications. The company offers proprietary products such as LentiBOOST for enhancing lentiviral transduction and AAV Reference Standards, alongside custom viral vector engineering and manufacturing services for biotech and pharmaceutical clients developing gene and cell therapies.
Product overview
SIRION Biotech, now integrated into Revvity's gene delivery team with 20 years of experience, offers a comprehensive viral vector portfolio covering adeno-associated viruses (AAVs), lentiviruses (LV), and adenoviruses (AVs) for early discovery and preclinical research stages. The portfolio centers on three core product categories: viral vector development and manufacturing services (Viral Vector Engineering and Manufacture, Gene Delivery Licensing), transduction enhancement technologies (LentiBOOST™ Technology), and capsid development solutions (AAV Capsid Development with nanobody targeting). Additional offerings include adenoviral vectors (Ad19a/64), reference standards (AAV Reference Standards, rAAV8 Reference Standard Material), licensing platforms (CHOSOURCE, Pin-point™ Base Editing, AAV Production), and supporting tools across genomic analysis, CRISPR, and RNA interference. The offering represents a platform-plus-services model where core viral vector products are complemented by specialized licensing and contract manufacturing services across the gene therapy development continuum.
Differentiator
Problem solved
Functional benefit
Products and services
- LentiBOOST Proprietary transduction enhancer reagent that significantly improves lentiviral transduction efficiency in difficult-to-transduce cell types, used by gene therapy developers for cell and gene therapy manufacturing.
- AAV Reference Standards Full viral particle-based reference materials for multiple AAV serotypes used in gene therapy quality control, biodistribution studies, and analytical method development.
- Ad19a/64 Adenoviral Vector Technology Proprietary adenoviral vector platform based on engineered chimeric fiber proteins for broad tissue tropism, used in gene therapy, vaccines, and oncolytic virotherapy applications.
- Viral Vector Engineering Services Custom contract development and engineering services for lentiviral, AAV, and adenoviral vectors, providing biotech and pharmaceutical clients with tailored vector design, optimization, and production for gene therapy programs.
Companies that use SIRION BIOTECH
Customer profileSegments3 records
Ideal customer profiles1 record
SIRION BIOTECH technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
SIRION BIOTECH partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights5 records
SIRION BIOTECH competitors and assessment
Company assessmentDirect peers
- Yposkesi: European viral vector CDMO specializing in AAV and lentiviral GMP manufacturing for gene and cell therapy developers — overlapping SIRION's custom manufacturing service offering with a similar European footprint.
- Aldevron: Manufactures viral vectors and plasmid DNA for gene therapy developers, with a comparable catalog-plus-services revenue model including reference-grade materials for gene therapy QC.
- Genezen: Viral vector CDMO focused on lentivirus and AAV for cell and gene therapy developers — closely comparable in services, customer mix, and stage of pipeline support.
- Cobra Biologics: A viral vector and plasmid CDMO (now part of Charles River Laboratories) offering AAV and lentiviral vector development and GMP manufacturing — directly overlapping SIRION's core service offering for pharma/biotech customers.
- Vigene Biosciences: Preclinical-to-GMP AAV, lentivirus, and adenovirus CDMO (later integrated with AGC Biologics) — directly comparable to SIRION across the same three viral vector modalities and customer base.
- Vectalys: Lentiviral vector specialist offering custom LV production and transduction enhancers — directly comparable to SIRION's lentivirus platform and LentiBOOST-style offerings.
- CEVEC Pharmaceuticals: Developer of viral vector production technologies (including AAV) and licensing platforms for gene therapy manufacturing — overlapping with SIRION's capsid engineering and licensing posture.
Broad incumbents
- Catalent: Global CDMO with major gene therapy and viral vector manufacturing capacity (including Paragon Gene Therapy) — competes with SIRION for large, late-stage gene therapy manufacturing programs.
- Lonza: World's largest CDMO with significant viral vector and cell-and-gene-therapy manufacturing capacity — relevant incumbent competitor for global, large-scale programs that exceed SIRION's 11-50-employee footprint.
- AGC Biologics: Large-scale CDMO with viral vector and gene therapy capabilities (boosted by the Vigene acquisition) — broader portfolio than SIRION but a direct competing offering for GMP viral vector manufacturing.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
SIRION BIOTECH social profiles
Digital presenceSIRION BIOTECH financial estimates
Financial estimateRevenue estimate
Valuation estimate
SIRION BIOTECH leadership team
Management profileNumber of profiles
Profiles3 records
SIRION BIOTECH funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SIRION BIOTECH M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SIRION BIOTECH
What does SIRION BIOTECH do?
SIRION Biotech develops and manufactures viral vector technologies (lentiviral, AAV, and adenoviral) for gene therapy applications. The company offers proprietary products such as LentiBOOST for enhancing lentiviral transduction and AAV Reference Standards, alongside custom viral vector engineering and manufacturing services for biotech and pharmaceutical clients developing gene and cell therapies.
Is SIRION BIOTECH a public or private company?
SIRION BIOTECH is a private company. It is classified as corporate owned and is currently acquired.
When was SIRION BIOTECH founded?
SIRION BIOTECH was founded in 2007. It employs 11 to 50 people.
Where is SIRION BIOTECH based?
SIRION BIOTECH is headquartered in Martinsried, Germany, in the Europe region.
How does SIRION BIOTECH make money?
Two revenue lines are on record. Viral Vector Products and Services are the primary driver. The others are custom Manufacturing Services.
Who are SIRION BIOTECH's main competitors?
Direct peers on record are Yposkesi, Aldevron, Genezen, Cobra Biologics, Vigene Biosciences, Vectalys and CEVEC Pharmaceuticals. Broad incumbents are Catalent, Lonza and AGC Biologics.
Does SIRION BIOTECH have an API?
No public API is recorded for SIRION BIOTECH.
What industry is SIRION BIOTECH in?
SIRION BIOTECH's product category is Gene Therapy Viral Vector CDMO. Its primary akta.pro industry code is HLAAACAJ, Gene Therapy Vector Manufacturing & CDMO Services, with a secondary code of HLAAAKAD, Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral). Its NAICS code is 325414 and its SIC code is 2836.